Last reviewed · How we verify
Preservative-free artificial tears
Preservative-free artificial tears lubricate and hydrate the ocular surface to relieve symptoms of dry eye disease.
Preservative-free artificial tears lubricate and hydrate the ocular surface to relieve symptoms of dry eye disease. Used for Dry eye disease / keratoconjunctivitis sicca, Ocular surface irritation and discomfort.
At a glance
| Generic name | Preservative-free artificial tears |
|---|---|
| Also known as | PFAT |
| Sponsor | University Hospital, Ghent |
| Drug class | Ophthalmic lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Artificial tears are aqueous solutions that mimic natural tear composition, providing moisture and protective coating to the cornea and conjunctiva. The preservative-free formulation eliminates potential irritants from chemical preservatives, making it suitable for frequent dosing and sensitive eyes. These drops work through osmotic and lubricating effects to reduce friction and restore the tear film.
Approved indications
- Dry eye disease / keratoconjunctivitis sicca
- Ocular surface irritation and discomfort
Common side effects
- Transient blurred vision
- Mild ocular irritation
- Foreign body sensation
Key clinical trials
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
- A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes (PHASE3)
- Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction (PHASE4)
- Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST) (NA)
- Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye (PHASE2)
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (PHASE1)
- Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Preservative-free artificial tears CI brief — competitive landscape report
- Preservative-free artificial tears updates RSS · CI watch RSS
- University Hospital, Ghent portfolio CI